Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

FibroGen

Explore full profile

Discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs

San Francisco, United StatesFounded 1993Biotech & Life Sciences
Valuation $19M Market cap · 2026
Revenue $9.9M Latest reported FY

About FibroGen

FibroGen is a biopharmaceutical company focused on developing innovative therapies for serious and life-threatening diseases such as anemia, fibrosis, and cancer. The company operates in the global healthcare market, with a significant presence in China. FibroGen's business model revolves around research and development (R&D) of novel drugs, conducting clinical trials, and bringing these therapies to market upon regulatory approval. The company primarily serves patients suffering from chronic and severe conditions, aiming to improve their quality of life through advanced medical treatments. Revenue is generated through the commercialization of approved drugs and strategic partnerships with other pharmaceutical companies. FibroGen's pipeline includes promising candidates like Roxadustat for anemia and Pamrevlumab for fibrosis and cancer, which are currently in various stages of clinical trials. The company is committed to responsible development and ethical practices, ensuring that their groundbreaking therapies reach those who need them the most.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1993
Headquarters
San Francisco, United States
Listing
IPO 2014
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later13 investors entered at this stage

  • Adage Capital
  • BioFund Management
  • Merlin Biomed
  • The Rosewood Corporation
  • Brookside Capital
  • Sigma Capital Group
  • Apothecary Capital
  • Goldman Sachs
  • Astellas Pharma
  • Daiwa Securities Group
  • Bain Capital
  • AstraZeneca
  • Morgan Stanley

Talent

Book a demo to see the people
Team profiled 43 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States65.2%
🇨🇳 China34.1%
🇵🇪 Peru0.6%
3 countries shown
Web traffic by country
4.6K monthly visits
across markets
🇺🇸 United States73.9%
🇮🇳 India28.3%
Top 2 markets shown

Patents

Estimated portfolio value
$36M

19 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about FibroGen on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See FibroGen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles